Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline
HL Kindler, N Ismaila, SG Armato III… - Journal of Clinical …, 2018 - ascopubs.org
Purpose To provide evidence-based recommendations to practicing physicians and others
on the management of malignant pleural mesothelioma. Methods ASCO convened an …
on the management of malignant pleural mesothelioma. Methods ASCO convened an …
Rare thoracic cancers: a comprehensive overview of diagnosis and management of small cell lung cancer, malignant pleural mesothelioma and thymic epithelial …
DW Dumoulin, P Bironzo, F Passiglia… - European …, 2023 - Eur Respiratory Soc
Despite the progress in outcomes seen with immunotherapy in various malignancies,
including nonsmall cell lung cancer, the benefits are less in small cell lung cancer …
including nonsmall cell lung cancer, the benefits are less in small cell lung cancer …
EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study
MG Zauderer, PW Szlosarek, S Le Moulec… - The Lancet …, 2022 - thelancet.com
Background Treatment options for malignant pleural mesothelioma are scarce.
Tazemetostat, a selective oral enhancer of zeste homolog 2 (EZH2) inhibitor, has shown …
Tazemetostat, a selective oral enhancer of zeste homolog 2 (EZH2) inhibitor, has shown …
Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies
Malignant pleural mesothelioma (MPM) is a rare but aggressive malignancy of the pleura,
with a strong causal link to asbestos exposure. MPM incidence has been increasing in …
with a strong causal link to asbestos exposure. MPM incidence has been increasing in …
[HTML][HTML] Current and future management of malignant mesothelioma: a consensus report from the national cancer institute thoracic malignancy steering committee …
AS Tsao, OW Lindwasser, AA Adjei… - Journal of Thoracic …, 2018 - Elsevier
Abstract On March 28–29, 2017, the National Cancer Institute (NCI) Thoracic Malignacy
Steering Committee, International Association for the Study of Lung Cancer, and …
Steering Committee, International Association for the Study of Lung Cancer, and …
Vinorelbine and gemcitabine as second-or third-line therapy for malignant pleural mesothelioma
MG Zauderer, SL Kass, K Woo, CS Sima, MS Ginsberg… - Lung Cancer, 2014 - Elsevier
Objectives Pemetrexed-cisplatin is the only FDA-approved regimen for malignant pleural
mesothelioma (MPM), and the impact on survival is modest. No drugs have been shown to …
mesothelioma (MPM), and the impact on survival is modest. No drugs have been shown to …
The ERK–ZEB1 pathway mediates epithelial–mesenchymal transition in pemetrexed resistant lung cancer cells with suppression by vinca alkaloids
LY Chiu, IL Hsin, TY Yang, WW Sung, JY Chi… - Oncogene, 2017 - nature.com
High thymidylate synthase (TS) level in cancer tissue is considered to result in resistance to
pemetrexed therapy for advanced stages of nonsquamous non-small cell lung cancers. To …
pemetrexed therapy for advanced stages of nonsquamous non-small cell lung cancers. To …
[HTML][HTML] Genomic and transcriptomic analyses identify a prognostic gene signature and predict response to therapy in pleural and peritoneal mesothelioma
Malignant mesothelioma is an aggressive cancer with limited treatment options and poor
prognosis. A better understanding of mesothelioma genomics and transcriptomics could …
prognosis. A better understanding of mesothelioma genomics and transcriptomics could …
Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti–PD-1 antibody in patients with mesothelioma and mouse tumor models
Q Jiang, A Ghafoor, I Mian, D Rathkey… - Science translational …, 2020 - science.org
LMB-100 is an immunotoxin targeting the cell surface protein mesothelin, which is highly
expressed in many cancers including mesothelioma. Having observed that patients …
expressed in many cancers including mesothelioma. Having observed that patients …
[HTML][HTML] Epidemiology, diagnosis and treatment of the malignant pleural mesothelioma, a narrative review of literature
SO Schumann, G Kocher, F Minervini - Journal of thoracic disease, 2021 - ncbi.nlm.nih.gov
The malignant pleural mesothelioma is a very aggressive tumor which is arising from
mesothelial cells and is associated with asbestos exposure. It is a heterogeneous cancer …
mesothelial cells and is associated with asbestos exposure. It is a heterogeneous cancer …